PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.48%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
3.86%
Positive operating income growth while TRVN is negative. John Neff might view this as a competitive edge in operations.
-1.47%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
12.77%
Positive EPS growth while TRVN is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
13.49%
Positive diluted EPS growth while TRVN is negative. John Neff might view this as a strong relative advantage in controlling dilution.
16.41%
Share count expansion well above TRVN's 3.15%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
17.29%
Diluted share count expanding well above TRVN's 3.15%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
23.86%
Positive OCF growth while TRVN is negative. John Neff would see this as a clear operational advantage vs. the competitor.
23.57%
Positive FCF growth while TRVN is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-21198.65%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-19211.55%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-43.46%
Negative 3Y OCF/share CAGR while TRVN stands at 21.92%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-15978.83%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-50766.69%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
48.21%
Positive short-term CAGR while TRVN is negative. John Neff would see a clear advantage in near-term profit trajectory.
19776.75%
Below 50% of TRVN's 51350.72%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
4394.26%
Below 50% of TRVN's 51350.72%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
625.15%
Positive short-term equity growth while TRVN is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
30.51%
Positive asset growth while TRVN is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
8.68%
Positive BV/share change while TRVN is negative. John Neff sees a clear edge over a competitor losing equity.
No Data
No Data available this quarter, please select a different quarter.
-31.37%
Our R&D shrinks while TRVN invests at 23.10%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
108.24%
SG&A growth well above TRVN's 7.49%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.